Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by smush74on Jan 06, 2015 5:02pm
116 Views
Post# 23291510

RE:NASDAQ Listing

RE:NASDAQ Listingnew company request 25K

New Company
Application
and Entry
:
The application fee is $25,000 for the Global or Global Select
Market, $5,000 for the Capital Market, and $1,000 for companies applying to list Closed End Funds,
Exchange Traded Fund
s, Index Fund Shares or other structured products.
The remainder of the entry
fee is due prior to the first
day of trading.
If the Company does not list within 12 months
of
submitting its application
, it will be assessed an additional non
-
refundable $5,0
00 application fee each
12 months thereafter to keep its application open.
Nasdaq will credit all application fees paid by the
Company in connection with an application that has not been closed towards the Entry Fee payable
upon listing.

nasdaq

Bullboard Posts